Supplementary Material for: Hedgehog pathway- and PD-1 inhibitors for advanced basal cell carcinoma

Here we report in detail the management of three complex advanced BCC (aBCC) cases treated with nivolumab and pembrolizumab after vismodegib failure. All patients were treated with PD-1 inhibitors before cemiplimab was approved by the FDA and EMA. On all tumors next generation DNA sequencing in the Center for Personalized Cancer Treatment-02 (CPCT-02) study was performed and subsequently patients were included in the Drug Rediscovery Protocol (DRUP) trial, in which treatment was started with commercially available targeted anti-cancer drugs based on the molecular tumor profile.